Avastin News and Research

RSS
Avastin is a biologic antibody designed to specifically bind to a protein called vascular endothelial growth factor (VEGF) that plays an important role throughout the lifecycle of the tumor to develop and maintain blood vessels, a process known as angiogenesis. Avastin is designed to interfere with the blood supply to a tumor by directly binding to the VEGF protein to prevent interactions with receptors on blood vessel cells. Avastin does not bind to receptors on normal or cancer cells. The tumor blood supply is thought to be critical to a tumor’s ability to grow and spread in the body (metastasize).
Ovarian cancer patients with molecular subtypes benefit from bevacizumab

Ovarian cancer patients with molecular subtypes benefit from bevacizumab

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Amgen presents extended analysis of PEAK study data at ASCO

Amgen presents extended analysis of PEAK study data at ASCO

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

Epirus Biopharmaceuticals to merge with Zalicus

Epirus Biopharmaceuticals to merge with Zalicus

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

Physician performs research on cervical cancer

Physician performs research on cervical cancer

Avastin can prolong the lives of women with advanced cervical cancer

Avastin can prolong the lives of women with advanced cervical cancer

Bevacizumab offers no benefit for patients newly diagnosed with glioblastoma

Bevacizumab offers no benefit for patients newly diagnosed with glioblastoma

Agenus' Prophage vaccine Phase 2 study hailed in Neuro-Oncology journal

Agenus' Prophage vaccine Phase 2 study hailed in Neuro-Oncology journal

Biothera enhances innate immune responses to Imprime PGG drug candidate

Biothera enhances innate immune responses to Imprime PGG drug candidate

RTOG phase II clinical trial of Bevacizumab (Avastin) shows positive results for treatment of cervical cancer

RTOG phase II clinical trial of Bevacizumab (Avastin) shows positive results for treatment of cervical cancer

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Glioblastoma multiforme patients treated with experimental vaccine show improved survival

Glioblastoma multiforme patients treated with experimental vaccine show improved survival

Drugmaker pushes new drug over cheaper equivalent at Medicare's expense

Drugmaker pushes new drug over cheaper equivalent at Medicare's expense

First Edition: December 9, 2013

First Edition: December 9, 2013

Researchers find correlation between biomarker and patient’s ability to respond to Imprime PGG

Researchers find correlation between biomarker and patient’s ability to respond to Imprime PGG

Phase 1/2 clinical trial data for VAL-083 in glioblastoma is presented at 18th Annual SNO meeting

Phase 1/2 clinical trial data for VAL-083 in glioblastoma is presented at 18th Annual SNO meeting